To help CDC increase understanding of the effectiveness of using maternal tenofovir containing combination drug during the second and third trimesters of pregnancy for the prevention of mother-to-child transmission of HIV and HBV in co-infected mothers.

To measure the levels of phthalates and their association with potential birth outcomes in a population of pregnant women living in Puerto Rico.